NinesMeasure
Contact for pricing
Regulatory Status Disclosed
Overview
NinesMeasure is an artificial intelligence-enabled software tool designed to assist radiologists in analyzing and reviewing adult thoracic computed tomography (CT) images. Originally developed by Nines and subsequently acquired by Sirona Medical, the tool is integrated into Sirona’s cloud-native RadOS platform to support diagnostic workflows.
The tool is built for trained radiologists operating in hospitals, health systems, and private radiology practices. It fits directly into the diagnostic viewing and reporting workflow, helping clinicians evaluate pulmonary nodules.
Notable capabilities of NinesMeasure include:
- Semi-Automated Measurements: Based on a radiologist’s input indicating the location of a pulmonary nodule, the algorithm automatically calculates the long and short axis diameter measurements in the axial plane.
- 2D Segmentation: The tool performs 2D segmentation and measurement on digital imaging and communications in medicine (DICOM) data.
- Inter-Study Consistency: It assists clinicians in tracking and comparing nodule size progression across multiple thoracic studies over a patient’s treatment program.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered lung nodule segmentation
- Automated long and short axis measurement of pulmonary nodules
- Quantitative information on nodule size
- Supports single study or series of studies analysis
- Improves inter-study consistency
- Enhances radiologist workflow efficiency
- Accelerates diagnosis of respiratory diseases
- High accuracy in nodule measurement
Use Cases
- Lung nodule measurement on CT scans
- Monitoring lung nodule size progression over time
- Assisting radiologists in diagnosing respiratory diseases
- Improving efficiency in radiology workflows
What Physicians Need to Know
Key Capabilities
NinesMeasure is a semi-automatic AI-powered tool for radiologists, designed to measure lung nodules on adult thoracic CT images. It accurately computes long and short axis measurements of selected nodules using machine learning algorithms.
Clinical Utility
The tool significantly reduces the time radiologists spend on pulmonary nodule measurement, improving time to diagnosis for patients. It enhances inter-study consistency throughout a patient's treatment and contributes to a reported 40% gain in efficiency for radiology customers by streamlining workflow and reducing administrative tasks.
Integration Options
NinesMeasure is designed to operate over a standard network interface and integrate with standard Picture Archiving and Communication Systems (PACS). The AI capabilities and technology of Nines, including NinesMeasure, were acquired by Sirona Medical in February 2022 and are being integrated into Sirona's Radiology Operating System (RadOS) for a unified platform experience.
Compliance Status
NinesMeasure received 510(k) clearance from the U.S. Food & Drug Administration (FDA) in March 2021, marking it as a legally marketed medical device.
Pricing Model
Specific pricing details for NinesMeasure are not publicly available. Following its acquisition by Sirona Medical, it is likely offered as part of Sirona's RadOS platform, which would have its own commercial model.
User Experience
Developed by a collaborative team of radiologists and engineers, NinesMeasure aims for a user-friendly experience, enabling quick and accurate nodule measurements. Its integration into Sirona's RadOS is intended to create a cohesive user experience by unifying various radiology applications.
Implementation Complexity
The tool is designed for straightforward integration into existing radiology workflows, utilizing standard network interfaces and PACS. Its incorporation into Sirona's RadOS suggests a simplified deployment within a broader, unified radiology platform.
Evidence Base
The algorithm's performance was validated through a retrospective, multicenter image comparison study, demonstrating high accuracy in measuring long and short axis diameters of nodules. FDA 510(k) clearance further supports its safety and effectiveness.
Physician Tip
NinesMeasure offers a significant advantage in radiology by automating the tedious task of lung nodule measurement, freeing up radiologists' time and improving diagnostic turnaround. Its ability to maintain inter-study consistency is crucial for effective patient treatment monitoring. While it enhances efficiency, remember that it's a semi-automatic tool intended to aid, not replace, the radiologist's expert evaluation and final diagnosis. Leverage its integration with PACS for a smoother workflow.
NinesMeasure is built for compatibility with standard PACS environments, ensuring relatively easy integration into existing imaging infrastructure. The acquisition by Sirona Medical means that future integrations and a more unified experience will likely be through Sirona's RadOS platform, which aims to consolidate various radiology applications for enhanced workflow efficiency.
Details
| Category | Oncology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing — Not publicly disclosed; likely enterprise-level licensing |
| Deployment | Cloud-based (integrated with teleradiology practice) and potentially in-house use |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Yes AI-estimated NinesMeasure received 510(k) FDA clearance (K202990) on February 25, 2021, as a Class II radiological image processing system. It is intended for use by trained radiologists to aid in the analysis and review of adult thoracic CT images for lung nodule measurement. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pulmonology, Radiology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate NinesMeasure
Press & Coverage
Imaging Technology News
FDA Clears Nines Lung Nodule Measurement Tool Built with AI
Nines announced FDA 510(k) clearance for NinesMeasure, an AI-powered lung nodule measurement tool designed to accelerate diagnoses of respiratory diseases and improve radiologist efficiency. This marks their second FDA clearance in 10 months, following an AI technology for triaging mass effect conditions and intracranial hemorrhages.
2021-03
Applied Radiology
AI-Based Lung Nodule Measurement Tool Receives FDA Clearance
Nines received FDA 510(k) clearance for NinesMeasure, an AI-driven lung nodule measurement tool aimed at speeding up respiratory disease diagnoses and enhancing radiologist workflow. The company highlights that it's the only FDA-cleared tool of its kind developed by a combined team of radiologists and engineers.
2021-03
BioWorld
FDA clears Nines' AI-based lung nodule measurement tool
Teleradiology company Nines Inc. secured 510(k) FDA clearance for NinesMeasure, an AI-powered tool for measuring lung nodules to expedite respiratory disease diagnoses. The company also reported a 40% increase in radiologist efficiency due to clinical workflow enhancements.
2021-03
AuntMinnie
AI market churn continues as Sirona buys AI assets from Nines
Sirona Medical acquired Nines' AI division, including the FDA-cleared NinesMeasure lung nodule analysis algorithm and NinesAI EmergentTriage algorithm. These algorithms will be integrated into Sirona's cloud-native RadOS platform.
2022-02
Diagnostic Imaging
FDA Clears Lung Nodule Measurement Tool from Nines Radiology
Nines Radiology announced FDA 510(k) clearance for NinesMeasure, an AI-based lung nodule measurement tool aimed at accelerating respiratory diagnoses. This is their second FDA clearance in 10 months, and the company also noted a 40% efficiency gain in clinical workflow.
2021-03
Medimaging.net
AI Tool Measures Lung Nodules with High Accuracy
NinesMeasure, a semi-automatic AI tool from Nines, is designed for trained radiologists to accurately measure lung nodules on adult thoracic CT images. The tool automates a time-consuming process, providing quantitative information on nodule size.
2021-04
Radiology Business
Nines wins FDA clearance for AI lung nodule measurement ...
Teleradiology services provider Nines received U.S. Food and Drug Administration (FDA) 510(k) clearance for NinesMeasure, a semiautomatic artificial intelligence tool for lung nodule measurement.
2021-03
AJR (American Journal of Roentgenology)
Artificial Intelligence (AI) for Lung Nodules, From the AJR Special Series on AI Applications
NinesMeasure is listed as an FDA-approved AI tool for lung nodule detection and segmentation, providing 2D measurements (long and short axes). This article discusses the role of AI in lung nodule evaluation and the challenges of clinical implementation.
2022-06
Videos
Product demos, reviews, and walkthroughs for NinesMeasure.
NinesMeasure by Nines
Frequently Asked Questions
NinesMeasure is designed to integrate with standard Picture Archiving and Communication Systems (PACS). Radiologists can indicate the location of a pulmonary nodule on a DICOM image, and the AI algorithms will automatically perform and display the measurements for review and editing. This semi-automatic tool aims to streamline the tedious and time-consuming process of manual nodule measurement.
NinesMeasure is specifically indicated for use on solid pulmonary nodules in adult thoracic CT images. It provides quantitative information by measuring the long and short axis diameters of selected nodules in the axial plane, which can be used for single studies or tracking changes over time.
Yes, NinesMeasure has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance signifies that the device is substantially equivalent to legally marketed predicate devices, and it is intended to be used as a measurement tool by trained radiologists, not as a replacement for full patient evaluation or diagnosis.
NinesMeasure automates the measurement of lung nodules, aiming to reduce the time and tedium associated with manual measurements while providing high accuracy. It also helps address inter-study consistency over a patient's treatment program. While the search results mention other AI tools for different purposes, NinesMeasure's FDA clearance and development by a combined team of radiologists and engineers are highlighted as unique for lung nodule measurement.
The provided search results do not contain specific information regarding the pricing model, tiers, or subscription options for NinesMeasure. For detailed pricing inquiries, it would be necessary to contact Nines, Inc. directly.
NinesMeasure is limited for use only on solid pulmonary nodules and is intended as a measurement tool, not to replace full patient evaluation or to make or confirm a diagnosis. While specific biases for NinesMeasure were not detailed in the provided information, general concerns about potential biases in AI systems, which rely on their training data, are relevant in healthcare.
Suggest an Edit →
| Last Verified: 2026-04-18 | First Added: 2026-04-18